Thanks for emailing that article!
Glaucoma Research Foundation hosted the 7th Annual Glaucoma 360 New Horizons Forum on February 9th in San Francisco. More than 50 companies and institutions were featured during a full day of presentations, panels, and discussions with leaders from start-up companies, industry executives, ophthalmic experts, venture capitalists, and the FDA.
One special focus of this year’s Forum was the use of virtual reality in glaucoma care, with presentations on VR in research and product development.
The New Horizons Forum was founded by Adrienne Graves, PhD, and Andrew G. Iwach, MD — both members of the Glaucoma Research Foundation Board of Directors — to highlight and further the advancement of new developments in glaucoma treatment.
Dr. Iwach, director of the Glaucoma Center of San Francisco, explains, “New Horizons Forum brings together a wide range of potential partners focused on innovation. From a physician standpoint, we need better solutions to help patients, and this meeting fosters the necessary collaboration and partnerships needed to advance new ideas.” He adds, “The goal of Glaucoma 360 is to accelerate the process to develop new glaucoma treatments to help patients today, and ultimately find a cure.”
Iqbal Ike K. Ahmed, MD, Medical Director, Prism Eye Institute, Assistant Professor at the University of Toronto, and Clinical Professor at the University of Utah, delivered the Drs. Henry and Frederick Sutro Memorial Lecture, the Forum’s keynote address. His topic was “Interventional Glaucoma: The Why, The Who, and The How.”
Dr. Ahmed’s keynote highlighted the evolving place of surgery in the glaucoma treatment paradigm. “It's a time for change, partly because the current treatment paradigm is not working well,” he said. “In addition, the advent of micro-invasive glaucoma surgery (MIGS) has opened up new opportunities to control primary open-angle glaucoma with earlier intervention.”
Dr. Ahmed stressed that interventional glaucoma is an attitude shift that involves early and aggressive intervention: “We need to break the cycle and move from being reactive, and reacting to a problem after it arises, to being much more proactive and preventing problems before they arise.”
Dr. Ahmed, who also serves on the New Horizons Program Committee, remarked that Glaucoma 360 is “an excellent networking opportunity since all the key individuals involved in innovation are at Glaucoma 360.” He adds, “As a clinician, it is exciting to see what is on the horizon in the treatment of glaucoma and have a meeting focused on pushing new developments forward to improve patient outcomes.”
The 2019 Glaucoma 360 New Horizons Forum will be held on February 1st in San Francisco. For more information, please visit www.glaucoma360.org.
Last reviewed on April 13, 2018